Back to Agenda
Session 3A (Nonclinical Track): Immunogenicity Assessment for Oligonucleotides
Session Chair(s)
Rosanne Seguin, PhD
McGill University, Canada
L. Peyton Myers, PhD
Senior Pharmacology and Toxicology Reviewer; Div of Antiviral Products, CDER
FDA, United States
Instances of immunogenicity have been shown to affect the safety and pharmacokinetics of individual drug products. Is immunogenicity an important consideration for oligonucleotide therapeutics? This session will begin with a general overview of oligonucleotide immunogenicity then continue with presentations exploring assessments of immunogenicity associated with short- and long-duration oligonucleotide therapy.
Speaker(s)
Immunogenicity of Oligonucleotides
David Pisetsky, MD, PhD
Duke University Medical Center, United States
Department of Medicine
Assessments of Immunogenicity Associated with Long-Term Oligonucleotide Administration
John S. Grundy, PhD
Ionis Pharmaceuticals, Inc., United States
Vice President, DMPK & Toxicology
Immunogenicity of Oligonucleotide Therapeutics – Points to Consider
Philip Oldfield, PhD, MSc
Philip Oldfield Bioanalytical Consulting, Canada
President
Have an account?